Study highlights disparities in lung cancer treatment access across Europe
“There are stark differences between European countries when it comes to both the reimbursement of, and access to, new treatments for patients with early-stage lung cancer. There are also differences in reimbursement times and indications between the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).”

J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
“Johnson & Johnson (JNJ Quick QuoteJNJ – Free Report) announced that the FDA granted full approval to its EFGR/MET inhibitor Rybrevant (amivantamab) in non-small cell lung cancer (NSCLC) indication. Following the FDA decision, Rybrevant, in combination with chemotherapy (carboplatin-pemetrexed), is approved for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.”

FDA lifts clinical hold on Iovance lung cancer trial
“SAN CARLOS, Calif. – Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company specializing in novel cancer therapies, announced today that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the IOV-LUN-202 trial. This pivotal study is assessing the efficacy of LN-145, a tumor infiltrating lymphocyte (TIL) cell therapy, in treating non-small cell lung cancer (NSCLC).”

Microbial signatures linked to immunotherapy response across cancers
“The microbiome can identify those who benefit from combination immunotherapy across multiple different cancers, including rare gynecological cancers, biliary tract cancers and melanoma. Researchers from the Wellcome Sanger Institute, the Olivia Newton-John Cancer Research Institute in Australia, and collaborators, have identified specific strains of bacteria that are linked with a positive response to combination immunotherapy in the largest study of its kind.”

Large-scale study explores link between smoking and DNA changes across six racial and ethnic groups
“Smoking changes the way genes are expressed, which later contributes to the development of lung cancer and other smoking-related illnesses. But the link between epigenetics (the study of mechanisms that impact gene expression) and smoking is not fully understood, especially in terms of differences across racial and ethnic groups.”

Lung Cancer in Women—Sociodemographic, Clinical and Psychological Characteristics with Comparison to Men
“Background: There is a difference in the course of lung cancer between women and men. Therefore, there is a need to evaluate various factors in the patient population treated in daily practice. The purpose of this study was to analyze the clinical, sociodemographic and psychological aspects of female lung cancer. To better express the results, we compared women and men.”

Evaluating the Feasibility of Lung Cancer Screening in High-risk Black Women CLINICAL TRIAL / NCT05898594
“The goal of this research study is to study U.S. Black women with a history of smoking to examine the feasibility, acceptability, and performance of low-dose computed tomography (LDCT) screening among this population. The name of the intervention used in this research study is: Low-dose computed tomography (radiologic scan) chest scan”

Creo device used in ‘groundbreaking’ lung cancer procedure
“Creo Medical Group announced a significant milestone in the field of minimally-invasive surgical endoscopy for cancer patients on Friday, with its ‘MicroBlate Flex’ device. The AIM-traded company announced that professor Pallav Shah and Dr Christopher Orton, specialists from the Royal Brompton Hospital, had successfully conducted the world’s first robotic-guided microwave ablation of lung tissue concurrently with a diagnostic procedure.”

Doctors Say These 4 Potential Signs Of Lung Cancer Are Something Everyone Should Know About
“According to the American Cancer Society, lung cancer is the leading cause of cancer death in the United States, accounting for 1 out of every 5 cancer fatalities. Early detection is imperative for increasing survival with lung cancer before the disease spreads beyond the lungs.”

Groundbreaking Atlas by MD Anderson Unveils New Pathways in Lung Cancer Detection and Treatment
“In the ongoing battle against lung cancer, a formidable enemy with a stealthy approach and devastating impact, a new weapon has been forged in the laboratories of The University of Texas MD Anderson Cancer Center. This cutting-edge tool, a comprehensive atlas of lung cells, promises to revolutionize our understanding and treatment of lung adenocarcinoma, the most common guise in which lung cancer presents itself.”

Nuvalent Granted FDA Breakthrough Therapy Designation for Non–Small Cell Lung Cancer Drug
“Nuvalent, Inc’s novel, brain-penetrant, ROS1-selective tyrosine kinase inhibitor (TKI) NVL-520 has been granted Breakthrough Therapy Designation by the FDA to treat patients with metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received prior therapy with at least two ROS1 TKIs.”

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes
“A recent real-world study observed that 24% of patients with advanced non–small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADOs) initiated nontargeted therapies before biomarker test results became available. This study assessed the clinical impact of the timing of first-line (1L) targeted therapies (TTs) in aNSCLC.”

FDA Awards Breakthrough Therapy Designation to Novel HER2-Activating NSCLC Therapy
“The FDA has granted a breakthrough therapy designation to BAY 2927088, an oral, small molecule tyrosine kinase inhibitor (TKI) for patients with non-small cell lung cancer (NSCLC) harboring HER2-activating mutations. Breakthrough therapy designation is intended to expedite the development and review of drugs that treat serious conditions and show improvement over currently available therapies. This designation marks a new potential treatment for the most common type of lung cancer.”

NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and other Cancer Types Based on Emerging Evidence
“PLYMOUTH MEETING, Pa., March 4, 2024 /PRNewswire/ — The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The evidence-based expert consensus recommendations are the most frequently updated guidelines for any area of medicine and are used by cancer care providers worldwide to stay up to date on innovations. Recently, the alliance of leading cancer centers published updated versions for several high-incidence cancer types, including breast, colorectal, lung, and pancreatic.”


Expert Discusses Radiotherapy Recommendations for SCLC Management
“Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.”